elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q55426345-43BAB1C2-0C02-4B58-B088-4D6AAF5A3085
Q55426345-43BAB1C2-0C02-4B58-B088-4D6AAF5A3085
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55426345-43BAB1C2-0C02-4B58-B088-4D6AAF5A3085
ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.
P2860
Q55426345-43BAB1C2-0C02-4B58-B088-4D6AAF5A3085
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55426345-43BAB1C2-0C02-4B58-B088-4D6AAF5A3085
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
13ef7dbd246b72574b962920a70b1c4e10067e60
P2860
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.